StreetAlpha.app
Home › Stocks › PLSE

Pulse Biosciences, Inc. (PLSE)

Healthcare
$44.84
▼ −3.28%
LAST CLOSE · NOV 17

Pulse Biosciences develops nanosecond pulsed energy devices for tissue ablation, with a focus on treating heart rhythm conditions. It last closed at $44.84 on Nov 17, down 3.28% on the day. The average 12-month price target from 5 analysts is $68.20 (+52.1% from the last close), with a high of $74.00 and a low of $60.00. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (5 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print totaling $1.8M, the largest $1.8M.

AI Auto Pilots
Is PLSE in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$1.5M
+1637.2% vs a year ago
Net income
−$83.7M
−5603.9% margin
EPS (diluted)
−$1.21
Free cash flow
−$63.7M
−4263.9% margin
Valuation
Market cap
$3.3B
73.5M shares
P/E
–
No P/E while losing money
Price to sales
2207.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$36.7M
At Sep 30
Shareholder equity
$183.6M
Shares outstanding
73.5M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $1.4M$1.4MFY2021FY2022: $700K$700KFY2022FY2023: $0$0FY2023FY2024: $0$0FY2024FY2025: $350K$350KFY2025

From PLSE's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 5 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
5firms
5 Buy0 Hold0 Sell
Each firm's latest rating on PLSE in the past 90 days
Average 12-month target
$68.20
▲ 52.1% upside

Based on 5 analysts who set a price target on PLSE in the past 90 days. The average target is $68.20, with a high of $74.00 and a low of $60.00, compared with the last close of $44.84.

Low $60.00Avg $68.20High $74.00
Blue marker: last close $44.84
Highest target$74.00
Average target$68.20
Lowest target$60.00
Latest rating changes
Canaccord GenuityTarget raised
Nov 6Buy$58 → $74
NeedhamTarget raised
Nov 6Buy$58 → $64
OppenheimerMaintained
Oct 13Buy$60
Canaccord GenuityTarget raised
Oct 6Buy$43 → $58
BTIGInitiated
Sep 23Buy$70
DateFirmActionRatingPrice target
Nov 6Canaccord GenuityTarget raisedBuy$58 → $74
Nov 6NeedhamTarget raisedBuy$58 → $64
Oct 13OppenheimerMaintainedBuy$60
Oct 6Canaccord GenuityTarget raisedBuy$43 → $58
Sep 23BTIGInitiatedBuy$70
Loading…

Technical Analysis

PLSE · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend

The stock is 18% below its 20 day and 15% below its 50 day average. It is 25% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 38). The nearest support is the Pivot at $44.79, and the nearest resistance the 100 day average at $45.00.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityHigh, 9.0%/day
Key levels
$58.9452 week high+31.4%
$52.8520 day average+17.9%
$51.6450 day average+15.2%
$46.45Pivot R1+3.6%
$45.90Swing high (Aug 7)+2.4%
$45.00100 day average+0.4%
$44.84Last close
$44.79Pivot−0.1%
$43.32Swing low (Oct 16)−3.4%
$43.18Pivot S1−3.7%
$33.66200 day average−24.9%
$12.5652 week low−72.0%
Indicators
RSI (14)38.38Weak, oversold below 30Neutral
MACD-0.39Below its signal lineBearish
Stochastic5.2Near the bottom of its rangeOversold
ADX (14)20.2Weak trend
Williams %R-89.2Oversold below −80, overbought above −20Oversold
CCI (20)-307.5Oversold below −100, overbought above 100Oversold
Rate of change−14.1%Change over 10 sessionsBearish
ATR (14)$4.03Typical daily range, 9.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for PLSE

What happened before

See how PLSE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow PLSE usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How PLSE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in PLSE in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$1.8M
Largest print
$1.8M
Loading…

PLSE Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲93 buying vs 37 selling
  • ▲Held by funds +6.3 pts
  • ▲Funds holding +36
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding142106+34.0%
In funds' top 1000–
Held by funds20.9%14.6%+6.3 pts
New / increased43 / 5020 / 43+47.6%
Reduced / sold out28 / 921 / 10+19.4%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PLSE institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PLSE is in one of them and how their past PLSE trades turned out.

PLSE in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PLSE in an article yet. Here's the latest on the wider market.

About Pulse Biosciences

Pulse Biosciences is a medical device company based in Hayward, California. It develops technology that delivers very short pulses of electrical energy to clear or kill targeted cells without heating the surrounding tissue. Its nPulse System and Vybrance Percutaneous Electrode are designed for surgeons and clinical sites performing soft tissue ablation. The company is also developing cardiac surgical and catheter devices for treating atrial fibrillation, a heart rhythm condition.

Headquarters
Hayward, CA